Physician profile
Emery D Jaffe
NPI 1396791448
$6,833.89
in general payments reported to CMS, 2019-2025
22 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $315 · 2021: $988 · 2022: $653 · 2023: $1,106 · 2024: $1,293 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,905.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.55 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $805.97 | 2021-2025 | Catalys System, Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $659.72 | 2019-2021 | |
| Sight Sciences, INC. | $578.70 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $550.86 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Alcon Vision LLC | $459.00 | 2019-2024 | Rocklatan, Simbrinza, Rhopressa |
| Horizon Therapeutics Plc | $399.57 | 2020-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $359.47 | 2019-2021 | |
| New World Medical,INC. | $309.86 | 2024-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Biotissue Holdings INC. | $248.75 | 2019-2025 | |
| Dompe US, INC. | $242.36 | 2024-2025 | Oxervate |
| Beaver-Visitec International, INC. | $197.93 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $189.81 | 2025 | Xdemvy |
| Allergan, INC. | $176.92 | 2019-2021 | |
| Amgen INC. | $122.50 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $112.13 | 2024 | Envista Mx60 Iol |
| Thea Pharma INC. | $89.60 | 2024-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $43.71 | 2019-2020 | |
| Alcon Research LLC | $24.79 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.58 | 2024 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $14.29 | 2022 | |
| Ocular Therapeutix, INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emery Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.